Abstract
The new tetracyclic compound savoxepine exhibits potent antidopaminergic effects with preferential activity in the hippocampus as compared to striatum in rat brain. As a result of behavioural animal models and regional differences in dopamine receptor binding characteristics, it has been suggested to possess an “atypical” neuroleptic response pattern. In an open clinical trial, savoxepine was administered to 12 in-patients suffering from paranoid schizophrenia and schizophreniform disorder (DSM-III). Eight patients were treated with a stable dose of 0.5 mg per day throughout the study, while in the remaining patients higher doses up to 20 mg/day were administered. Mean total BPRS scores and subscores demonstrated a moderate improvement of mainly positive schizophrenic symptoms. In contrast to animal test results, savoxepine in a broad dose range produced typical untoward extrapyramidal symptoms in the majority of patients. Our results indicate that savoxepine may not possess the expected “atypical” neuroleptic response pattern, and that the predictive validity of the animal models in question used to separate antipsychotic effects from extrapyramidal reactions may be ill-founded.
References
Bischoff S, Vassout A, Delini-Stula A, Waldmeier P (1986) Interactions of cipazoxapine, citatepine, eresepine, and maroxepine with central dopamine (DA) receptors: effects of in vivo [3H]spiperone binding, DA metabolism, and behavioral parameters. Pharmacopsychiatry 19:306–307
Bischoff S, Krauss J, Stoecklin K, Heinrich M (1989) Biochemical basis for a loading dose therapy with the antipsychotic savoxepine. VIII World Congress of Psychiatry, Athens. Abstracts, Excerpta Medica, Abstract no 532, p 144
Butler B, Bech P (1987) Neuroleptic profile of cipazoxapine (savoxepine), a new tetracyche dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. Pharmacopsychiatry 20:122–126
Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatry 19:134–139
Gerlach J, Korsgaard S (1983) Classification of abnormal involuntary movements in psychiatric patients. Neuropsychiatr Clin 2:201–208
Möller HJ, Kissling W, Dietzfelbinger T, Stoll KD, Wendt G (1989) Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot study. Pharmacopsychiatry 22:38–41
Waldmeier PC, Bischoff S, Bittiger H, Hauser K, Vassout A, Delini-Stula A, Haeusler A, Schenkel L, Storni A (1986) Pharmacological profiles of four new tetracyclic dopamine antagonists. Pharmacopsychiatry 19:316–317
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wetzel, H., Wiedemann, K., Holsboer, F. et al. Savoxepine: invalidation of an “atypical” neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology 103, 280–283 (1991). https://doi.org/10.1007/BF02244218
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02244218